2017 American Transplant Congress
Update of a Placebo-Controlled Trial of C1 Esterase Inhibitor for Prevention of Antibody Mediated Rejection (ABMR) in Highly-HLA Sensitized Patients.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced ABMR and rebound B-cell activity. Pathologic features of…2017 American Transplant Congress
Healthcare Resource Utilization for Patients with Donor-Specific Antibodies Post-Kidney Transplantation.
Formation of de novo donor-specific antibodies (dnDSA) against human leukocyte antigens (HLA) contributes to inferior kidney transplant (KT) outcomes. No data exist on healthcare resource…2017 American Transplant Congress
Isolated Angiotensin II Receptor Type I Antibodies (AT1R) Are Not Associated with Active Antibody Mediated Rejection (ABMR) in Pediatric Renal Transplant Recipients.
Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
Intro: Donor specific antibodies (DSAs) detected post transplant are associated with ABMR and graft dysfunction. The role of non-HLA antibodies especially angiotensin II receptor type…2017 American Transplant Congress
Biological Interplay Between Circulating HLA-sp Alloreactive Memory B-Cells and Long-Lived Plasma Cells in Kidney Transplant Patients Undergoing Chronic ABMR.
Alloreactive humoral responses are one of the main causes of immune-mediated allograft injury in kidney transplantation. Different biological compartments are involved in the generation and…2017 American Transplant Congress
Meta-Analysis of Clinical Significance of Complement Activating Anti-HLA DSA in Kidney Transplantation.
Donor-specific anti-HLA antibodies (DSA) are currently recognized as the major limitation to access transplantation and the first cause of late transplant failures. The effect of…2017 American Transplant Congress
Assessing the Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients After Desensitization (Des) 2 Years Post Implementation.
Introduction: The new KAS aims to improve access to transplantation for HS patients, specifically CPRA 99-100%. Our center has extensive experience w. DES to improve…2017 American Transplant Congress
De Novo Donor-Specific Antibody Formation After Kidney Retransplant Is Associated with Specificity Against Class I.
Retransplant (RTx) patients are often sensitized due to donor-specific antibody (DSA) formation, with higher acute rejection rates during subsequent transplants vs patients without DSA. However,…2017 American Transplant Congress
Patient Outcomes Following the Disappearance of Donor Specific Antibody in Crossmatch Positive Simultaneous Liver-Kidney Transplant Recipients.
Background: Simultaneous liver and kidney transplantation (SLKT) remains as the gold standard for patients with chronic renal and liver diseases. Pre-transplant donor-specific antibody (DSA) to…2017 American Transplant Congress
A Novel 3-Dimensional Culture System Enables In Vitro Study of Human Bone Marrow Plasma Cells.
Purpose: Historically, in vitro study of human plasma cells (PCs) has been greatly limited by their short survival (48-72 hrs). Therefore, systems that maintain viability…2017 American Transplant Congress
Donor-Specific B Cell Responses: Predicting the Future of Kidney Transplants.
Allogeneic cell and tissue transplants nearly always evoke B cell responses ascertainable by detecting donor-specific antibodies (DSA) in the circulation of the recipient. DSA are…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 47
- Next Page »